TSNDF Stock Rises 6.5% in a Month: Time to Buy, Hold or Sell?

TerrAscend's Q2 2026 revenue rose 3.3% year over year to $67.1 million, while gross margin expanded 290bps to 54% and adjusted EBITDA margin increased 170bps year over year to 26.3%. The company generated $7.4 million in operating cash flow and $5.7 million in free cash flow, extending positive operating cash flow to 16 consecutive quarters, and guided to 2-3% Q3 revenue growth with 52-54% gross margins. Net debt remained elevated at $197.3 million despite refinancing and $15.5 million of first-half term-loan repayments; potential U.S. uplisting and federal cannabis reform remain contingent catalysts amid intense competition and regulatory uncertainty.

Analysis

TSND's central equity question is not whether operating execution can stabilize, but whether modest organic growth can outpace the combined drag from price compression, incremental store/cultivation capacity, and a highly levered capital structure. The reported margin improvement is more valuable if it reflects durable vertical-integration economics; however, a low-single-digit sales trajectory leaves little room for a wholesale-price reset or a ramp-related inventory write-down. In the next 1-3 months, third-quarter gross margin and free-cash-flow conversion—not adjusted EBITDA—are the key proof points.

The proposed exchange listing is a potential liquidity catalyst, but it should not be valued as an assured rerating. A reverse split can improve technical eligibility while doing nothing to broaden the institutional buyer base absent clearer federal legality, and conversion/refinancing instruments may create dilution overhang. With net debt roughly three times annualized EBITDA by a rough run-rate calculation, equity remains a residual claim: a 200-300bp margin reversal would materially slow deleveraging and compress the value investors assign to the operating platform.

Relative value favors GTBIF over TSND and CURA: Green Thumb's stronger scale and balance-sheet flexibility should let it defend share through price competition without sacrificing strategic capex. The contrarian positive for TSND is that a federal tax normalization for qualifying operations could cause free cash flow to improve faster than current EBITDA-based screens imply; the catalyst is regulatory implementation and cash-tax disclosures, not headline reform speculation. Thesis fails if quarterly revenue returns to decline, gross margin falls below 52%, or net debt stops declining by year-end.

Key Decisions for Investors

• Maintain TSND as a watchlist long rather than initiate into the current rally; buy only after Q3 demonstrates revenue growth above 3% and gross margin at or above 53%, with a 6-12 month target based on sustained deleveraging. Exit on gross margin below 52% or renewed negative free cash flow.
• Express competitive divergence over 6-12 months via long GTBIF / short TSND, sized beta-neutral. GTBIF offers better capacity to absorb Northeast price competition; close the spread if TSND posts two consecutive quarters of greater-than-5% growth while reducing net debt materially.
• Avoid treating an NDAQ/NYSE listing application as a standalone TSND catalyst. Add only after a formal listing approval and disclosed reverse-split ratio, while checking post-split liquidity, convertible terms, and institutional ownership response.
• Monitor cash taxes and free-cash-flow conversion following the medical-cannabis tax treatment change. If cash taxes fall without offsetting price deterioration, reassess TSND as a tactical long; absent that evidence, the regulatory upside remains unverified.